Ascendis Pharma Says Growth Drug Shows Benefits in Infants
Ascendis Pharma released positive 52-week data for TransCon CNP in infants with achondroplasia from its Phase 2 reACHin trial.
Ascendis Pharma tested a growth medicine on babies with a bone condition and saw good results after one year. When a medicine company shows real proof that sick babies get better, it tells you the company is making progress toward helping people.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.